Teva Pharmaceutical Industries, an Israeli multinational pharmaceutical company, was hit with an antitrust lawsuit Monday in New Jersey District Court in relation to its multiple sclerosis drug, Copaxone. The suit contends that Teva used coercive tactics to switch the market from 20mg to 40mg to suppress generic competition. The complaint was filed by Carella Byrne Cecchi Olstein Brody & Agnello; Hagens Berman Sobol Shapiro; Kessler Topaz Meltzer & Check and other plaintiff firms. Counsel have not yet appeared for the defendant. The case is 2:22-cv-01232, FWK Holdings, LLC et al v. Teva Pharmaceuticals Industries, Ltd. et al.
Biotech & Pharmaceuticals
March 07, 2022, 5:31 PM